Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
PlacementTracker Publishes First Quarter 2014 PIPE Market League Tables
-
UPDATE: Maxim Cuts Genco Shipping (GNK) to Sell, Price Target Slashed to $0.25
-
Liberty Media's Sale of Majority Barnes & Noble (BKS) Stake Presents Other Opportunities, Maxim Group Says
-
Del Mar Pharma (DMPI) Started at Buy at Maxim Group
-
Pre-Open Stock Movers 4/2: (MNKD) (ENVI) (XLRN) Higher; (AGEN) (LQDT) (AGU) Lower (more...)
-
New York Mortgage Trust (NYMT) Prices 13M Offering at $7.59/Share
-
IsoRay (ISR) PT Raised to $3.50 at Maxim
-
Maxim Group Starts Profire Energy (PFIE) at Buy
-
New Study Suggests Additional Upside for Harvard Apparatus (HART), Maxim Says
-
IsoRay (ISR) Closes 5.64M Common Offeing; Sees Net Proceeds of $13.8M
-
Arlington Asset Investment (AI) Prices 2.75M Offering at $27.40/Share
-
Orchid Island Capital Closes Public Offering of Common Stock
-
Pre-Open Stock Movers 3/24: (NUS) (MVIS) (HLF) Higher; (NBR) (NTAP) (WLT) Lower (more...)
-
Agenus (AGEN) Target Cut at Maxim Group; 'Buy' Maintained
-
Organovo Holdings (ONVO) Will Present at 2nd Annual Regen Med Investor Day
-
Maxim Group Upgrades Achillion Pharmaceuticals (ACHN) to Buy
-
IsoRay (ISR) Prices Offering at $2.60/Sh
-
Maxim Group Maintains Bullish Thesis on Galena Biopharma (GALE) Despite SEC Investigation
-
Maxim Group Doubles Price Target on Synthetic Biologics (SYN)
-
Aastrom Biosciences to Present at the 2014 Regen Med Investor Day
-
Orchid Island Capital (ORC) Prices 3.2M Offering at $12.55/Share
-
Orchid Island Capital Prices Public Offering of Common Stock
-
Anavex Successfully Closes $10 Million Financing to Initiate Phase 1b/2a Alzheimer's Clinical Trial
-
Notable Analyst Rating Changes 03/18: (HPQ) (VNET) (QGEN) Upgraded; (CSCO) (SINA) (EJ) Downgraded
-
Cesca Therapeutics to Present at Regen Med Investor Day March 26 in New York
-
Maxim Group Downgrades SINA Corporation (SINA) to Hold Post Weibo IPO
-
Inovio Pharmaceuticals (INO) Price Target Lifted to $6 at Maxim Group
-
Medivation (MDVN) Target Lifted at Maxim Group
-
Notable Analyst Rating Changes 03/14: (TEVA) (SIRI) (LOW) Upgraded; (PLUG) (XOXO) (NUE) Downgraded
-
Pre-Open Stock Movers 3/14: (HART) (MEET) (LMCA) Higher; (ARO) (ZBB) (PLUG) Lower (more...)
-
UPDATE: Maxim Group Sees Big Opportunity in Harvard Apparatus (HART), Starts at Buy w/PT of $19
-
Omeros (OMER) Prices 3.04M Common Offering at $11.50/Share
-
Galmed Pharmaceuticals (GLMD) IPO Opens Higher, Trends Lower
-
Maxim Group Upgrades PowerSecure (POWR) to Buy
-
StemCells, Inc. to Participate at 2014 Regen Med Investor Day in New York
-
Athersys to Present at Regen Med Investor Day March 26th in New York
-
BioLineRx (BLRX) Closes 9.66M ADS Offering for Gross Proceeds of $24.1M
-
Qihoo 360 (QIHU) Target Lifted to $130 at Maxim Group
-
Gilead Sciences (GILD) Bullish Stance Maintained at Maxim Group
-
Maxim Group Starts Energen (EGN) at Buy
-
Maxim Group Starts Paragon Shipping Inc. (PRGN) at Buy
-
Inovio Pharma (INO) Closes 21.8M Common Stock Offering
-
BioLineRx (BLRX) Prices 8.4M Offering at $2.50/ADS
-
BioLineRx (BLRX) Lower on Stock Offering
-
Dendreon (DNDN) Posts a Solid Quarter - Maxim Group
-
Magic Software (MGIC) Prices 6M Offering at $8.50/Share
-
Magic Software Enterprises Ltd. (MGIC) Announces Offering
-
Maxim Group Maintains Bullish View on Baidu (BIDU) Post Q4
-
Notable Analyst Rating Changes 02/26: (LNKD) (RRC) (ARIA) Upgraded; (PSA) (NIHD) (HUM) Downgraded
-
Maxim Group Upgrades ARIAD Pharmaceuticals (ARIA) to Buy


